Title: Compositions and Methods for Treatment of Hepatitis C Virus-Associated Diseases. Number: 20040033978. Filed: June 9, 2003. Lead Inventor: Kevin Anderson, Isis Pharmaceuticals.
The patent application, its abstract states, covers “antisense oligonucleotides … which are complementary to and hybridizable with at least a portion of HCV RNA, and which are capable of inhibiting the function of the HCV RNA.”